RXST: financial statements from SEC — TradeAlmanac

RXST

RxSight, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	134m	140m
Cost of revenue	31m	41m
Gross profit	103m	99m
Research and development	39m	34m
Selling, general and administrative	113m	101m
Operating expenses	151m	136m
Operating income	−48m	−37m
Interest expense	19,000	21,000
Pre-tax income	−39m	−27m
Income tax	66,000	50,000
Net income	−39m	−27m
Earnings per share	−0.95	−0.71
Earnings per share, diluted	−0.95	−0.71
Weighted average shares	41m	39m
Weighted average shares, diluted	41m	39m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	18m	20m	30m	40m	28m	17m	17m	25m
Short-term investments	200m	208m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−16m	−17m
Depreciation and amortisation	3m	4m
Share-based compensation	32m	25m
Capital expenditure	4m	5m
Investing cash flow	17m	−99m
Financing cash flow	2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)